# Effect of intramuscular diazepam infusion on herpes zoster-related pain in older patients: a randomized, double-blind, placebo-controlled trial

**Authors:** Bingjie Ma, Meiling Xu, Lu Yang, Xuehua Huang, Peiliang Wang, Yun Ji, Ke Ma

PMC · DOI: 10.1186/s12871-024-02576-9 · 2024-05-29

## TL;DR

A study found that intramuscular diazepam injections over three days reduced herpes zoster-related pain and improved sleep quality in older patients compared to a placebo.

## Contribution

This is the first randomized trial to show diazepam's effectiveness in managing herpes zoster pain in older adults.

## Key findings

- Diazepam reduced pain scores significantly compared to placebo on posttreatment days 3 and 4.
- Diazepam improved sleep quality as measured by PSQI scores on posttreatment day 7.
- No significant adverse reactions were observed in the diazepam group compared to placebo.

## Abstract

This study evaluated the effectiveness, psychological effects, and sleep quality using intramuscular diazepam infusion compared with placebo in patients with herpes zoster (HZ)-related pain.

The patients were randomized to either the diazepam or control group. The diazepam group received an intramuscular injection of diazepam for 3 consecutive days, while the control group received an intramuscular injection of 0.9% normal saline. The primary outcome was pain relief on posttreatment day 4, as measured using the Visual Analog Scale (VAS). Moreover, anxiety and depression were evaluated using the Generalized Anxiety Disorder-7 (GAD7) and Patient Health Questionnaire-9 (PHQ9), respectively. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI).

In total, 78 patients were enrolled in the trial. The mean differences in VAS scores between the two groups were 0.62 (P = 0.049) on posttreatment day 3 and 0.66 (P = 0.037) on posttreatment day 4. The effective rates of pain management in the diazepam group ranged from 10.26 to 66.67%, which were higher than those in the control group on posttreatment days 3 and 4 (P < 0.05). The mean difference in PSQI scores between the diazepam and control groups was 1.36 (P = 0.034) on posttreatment day 7. No differences were found in the incidence of analgesia-adverse 1reactions between the diazepam and placebo groups.

The intramuscular injection of diazepam for 3 consecutive days provides effective pain management and improves the quality of life. Our study suggests that diazepam is more effective than the placebo in patients with HZ-related pain.

The study was prospectively registered at https://www.isrctn.com/trialist(Registration date: 24/01/2018; Trial ID: ISRCTN12682696).

## Linked entities

- **Chemicals:** diazepam (PubChem CID 3016)
- **Diseases:** herpes zoster (MONDO:0005609)

## Full-text entities

- **Diseases:** Generalized Anxiety Disorder (MESH:C000726808), HZ (MESH:D006562), pain (MESH:D010146), anxiety (MESH:D001007), depression (MESH:D003866), analgesia (MESH:D000699)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11134619/full.md

---
Source: https://tomesphere.com/paper/PMC11134619